Viroclinics-DDL is now Cerba Research
New and improved benefits for you and your teams
Enhanced capabilities
By coming together with Viroclinics-DDL, the Cerba Group has extended our services to offer you preclinical research, clinical trial diagnostics, assay development, and virology clinical trial logistic services. Our enhanced capabilities give you access to in-house laboratory testing to support the development of vaccines, antibodies, and antiviral compounds targeting viral infectious diseases.
Integrated solutions
Together we provide clinical trial central and speciality laboratory services to give you a comprehensive portfolio of solutions and capabilities at every stage of clinical trials, from assay development in multiple therapeutic areas to the latest technology available in flow cytometry, immunohistochemistry, Next Generation Sequencing, and immunoassays.
Deepening therapeutic insight
As well as our unparalleled scientific expertise, you can draw on our fast-expanding portfolio of therapeutic areas, including Oncology and Immuno-Oncology, Metabolic Diseases, Virology and other Infectious Diseases, Inflammatory and Autoimmune Diseases, Neurology and Rare Diseases.
Industry-leading service
Our portfolio of scientific and technical expertise combined with our global capabilities, vast databases of patient data and samples, and best-in-class logistics removes the uncertainty from sample management, reduce risks, and enables the accuracy and acceleration of your drug and vaccine development projects from start to finish.
New highlights for your team
• Early stage and preclinical testing services, including in-house developed customized animal models.
• Access to biomedical and genetic data from over 45 million patients per year from across Europe, Africa, and North America.
• Capability to sequence 1000+ whole human genomes per week.
• Unique access to Africa’s growing population including diverse samples for non-clinical research.
• A gateway for customers to conduct studies in China with local capabilities within an integrated global solution.
• Access to exceptional scientific and technical teams in multiple treatment areas for drug and vaccine development.
• A cutting-edge specialist laboratory network of over 1000 labs including in-house BSL2 and BSL3 labs in Europe, the Americas, Africa, Asia and Australia.
• Largest global PBMC network
• Extended virus biobank services
• Access to specialty techniques including flow cytometry and anatomical pathology solutions.
• Molecular diagnostics expertise, supporting immuno-oncology, cell & gene therapy, and infectious diseases clinical trials.